First Manhattan’s NexImmune, Inc. Common Stock NEXI Stock Holding History

First Manhattan’s Portfolio NEXI Stock Details NEXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,964	Closed	-$31.3K	–	1600
2023 Q3	$31.3K	Hold	5,964	–	–	﹤0.01%	956
2023 Q2	$42K	Hold	5,964	–	–	﹤0.01%	914
2023 Q1	$56.7K	Buy	5,964 +4,964	+496%	+$52.1K	﹤0.01%	895
2022 Q4	$6.08K	Sell	1,000 -1,649	-62%	-$20.6K	﹤0.01%	1343
2022 Q3	$36K	Sell	2,649 -1,000	-27%	-$29.3K	﹤0.01%	984
2022 Q2	$146K	Hold	3,649	–	–	﹤0.01%	774
2022 Q1	$384K	Sell	3,649 -2,237	-38%	-$164K	﹤0.01%	635
2021 Q4	$678K	Hold	5,886	–	–	﹤0.01%	505
2021 Q3	$2.23M	Buy	+5,886	New	+$1.97M	0.01%	319

Other funds holding NEXI

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

First Manhattan's NEXI Position: Q4 2023 in Review

First Manhattan sold out of NexImmune, Inc. Common Stock (NEXI) in Q4 2023, closing a stake of 5,964 shares — an estimated $31.3K sold.

First Manhattan first reported a position in NEXI in Q3 2021 and held it in 9 quarters. The position peaked at $2.23M in Q3 2021. 11 funds tracked by Wall St. Rank hold NEXI as of Q4 2023.

First Manhattan reported no remaining NexImmune, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
First Manhattan sold 5,964 NexImmune, Inc. Common Stock shares in Q4 2023, an estimated $31.3K.
First Manhattan first reported a position in NexImmune, Inc. Common Stock in Q3 2021 and held it in 9 quarters.
First Manhattan's NexImmune, Inc. Common Stock position peaked at $2.23M in Q3 2021.
11 funds tracked by Wall St. Rank held NexImmune, Inc. Common Stock as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.